exenatide
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemia
Conditions
Hyperlipidemia
Trial Timeline
Jan 1, 2010 → Sep 1, 2011
NCT ID
NCT01056549About exenatide
exenatide is a pre-clinical stage product being developed by Eli Lilly for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01056549. Target conditions include Hyperlipidemia.
What happened to similar drugs?
6 of 20 similar drugs in Hyperlipidemia were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01373216 | Phase 3 | Completed |
| NCT01056549 | Pre-clinical | Completed |
| NCT00753896 | Phase 3 | Completed |
| NCT00529204 | Phase 2 | Terminated |
| NCT00516048 | Phase 3 | Completed |
| NCT01876849 | Phase 3 | Completed |
Competing Products
20 competing products in Hyperlipidemia